Michael Kranda Email and Phone Number
Background | Board & Product to Market Details | Skills | Patents Served in Executive, Operational, and Board roles for numerous private and public companies. Led multiple private rounds, IPOs, and M&A transactions, and product approvals. Passionate about driving growth, innovation and value creation. Summary of Board of Director Roles - Aclipse Therapeutics - NCE's for ALS and gastroparesis- Life Sprout Therapeutics - nano tech for tissue engineering and cell therapy applications - BEAT Bio - Cardio vascular gene therapy - PTC Therapeutics, also Chairman of Audit Committee - NCE's for rare diseases - Allen Brain Science Institute - Open source non-profit brain research institute- BiPar - PPAR molecule for the treatment triple negative breast cancer- Oxford GlycoSciences (OGS) - Proteomics platform plus approved product for Gaucher disease- Immunex - Pioneering immunology biotech Products Development Achievements / Approved Products - Leukine: Neutropenia- Enbrel : RA - TransLarna: DMD - Everysdi: Spinal muscular atrophy - Vevesca: Gaucher and NiemannSkills - Gene Therapy - Cell Therapy - Oncology- CNS - Orphan drugs- AI enabled cell- imaging- Manufacturing and Regulatory Affairs- Turnaround Situations- Leadership and Recruiting - Fundraising and BD - Board work and Governance - Venture CapitalPatents- Co-inventor on an application using machine learning algorithms and neural networks for non invasive 3D cell imaging in the production of cellular therapy's.
Aclipse Therapeutics
View- Website:
- aclipsetherapeutics.com
- Employees:
- 5
-
Board Member, Chief Business OfficerAclipse Therapeutics May 2023 - PresentKing Of Prussia, Pennsylvania, United StatesAclipse Therapeutics is a clinical stage company focused on molecular pathways that regulate cellular stress, protein misfolding and inflammation. We are currently developing two in-licensed clinical assets with 7 potential indications and existing $30 billion markets. M107 is primed to enter a Ph2 trial for the treatment of gastroparesis. M107 has the potential to modify the disease by restoring normal gastric pacemaker function.M102 is primed to enter a Ph 1 trial next year for the treatment of sporadic ALS and designed to activate both Nrf2 and HSF1 pathways. Further, we are developing biomarkers based on patient PBMCs to identify potential drug responders and exploring Parkinson’s and Friedreich’s Ataxia as potential additional indications.
-
Chief Executive Officer, Board MemberLifesprout Oct 2021 - Sep 2023LifeSprout is a tissue engineering and regenerative medicine platform company spun out of the Johns Hopkins Nanobiology Institute. Led efforts to turn around operations including delivery of a stalled pivotal clinical program that met the primary endpoint, delivery of company's first ISO 13485 certificate, and successful implementation of multiple manufacturing scale up and process improvement initiatives. Worked closely with the board to raise $3MM in Q1 and establish a robust strategic alternative and licensing process. -
Svp Cns Practice Lead And Head Of Alliance ManagementAsklepios Biopharmaceutical, Inc. (Askbio) Jul 2020 - Oct 2021Ask Bio, now Bayer, is a pioneering AAV gene therapy company dedicated to developing life-saving medicines to cure genetic diseases. Recruited to lead their CNS gene therapy business and support a dual track IPO/M&A process that resulted in Bayer's $4B acquisition. Managed clinical trials in Parkinson's, MSA, Huntington's and Alzheimer's disease. Integrated two CNS acquisitions and led efforts to improve/standardize MRI guided brain injection protocols, devices and software. Also served as corporate head of Alliance Management where I was able to cut over $25MM of non-priority programs and established Joint Steering Committees and other initiative's to improve the performance of core programs and strategic alliances. -
Senior Director Business Development Allen Institute For Brain Science And Founding Board MemberAllen Institute Jun 2017 - Jul 2020Seattle, WaThe Allen Institute's are non-profit research organizations founded by Microsoft Co-Founder Paul Allen. I served as a founding board member of the Allen Institute for Brain Science and was recruited back in 2017 to the parent Institute to implement an intellectual property management system and an industrial collaboration platform to further drive the impact of AI's research efforts via IP strategies, translational programs and industrial partnerships.Implemented a robust IP program, dramatically increased disclosures and led efforts to establish two patent families; modified AAV enhancers for brain cell type specific gene therapy applications and AI applications of machine learning algorithms and neural networks for 3D intracellular visualization.Sourced and negotiated two multi-indication CNS gene therapy collaborations based on the enhancers. Negotiated a license of the AI technology to a leading live cell imaging company.Am a co-inventor on an international stage patent filing covering use of the AI technology for cell therapy manufacturing and quality applications. -
Ceo, Member Of The BoardBeat Biotherapeutics 2013 - 2018Seattle, WashingtonUniversity of Washington spin out developing an AAV6 gene therapy for the treatment of chronic heart failure. Developed and manufactured a humanized gene construct.. Delivered a successful POC with the new construct and held a pre-IND meeting with the FDA.
-
Board Member And Audit Committee ChairmanPtc Therapeutics, Inc. 2003 - 2015South Plaifield, NjServed as a Board Member and Audit Committee Chair managing multiple strategic and financial transactions, including their IPO. Helped ramp up of global sales and marketing operations for transLarna, approved outside the US for DMD. Participated in the development and out-licensing of Evrysdi to Roche for the treatment of Spinal Muscular Atrophy. -
ChairmanCardero Therapeutics Jan 2010 - Jul 2012Cardero, now Epirium Bio, is a clinical stage biotech focused on the biology of mitochondrial biogenesis and tissue regeneration in neuromuscular and neurodegenerative diseases including Frederic's Ataxia and Becker muscular dystrophy.
-
Ceo, President, DirectorVaccinogen Inc. 2010 - 2012Frederick, MdCancer Vaccine and monoclonal antibody company
-
Chairman Of The BoardRaven Biotechnologies 2005 - 2008San Francisco Bay AreaTherapeutic cancer stem cell platform company.
-
Managing DirectorVulcan Capital Jan 2002 - Jan 2007Sourced and led a Series A in BiPar which was acquired by Sanofi generating a near 10x return. Represented Vulcan on the PTC Therapeutics Board and managed another significant exit. Achieved overall fund performance in the top decile of comparable US venture funds over the period. -
Ceo And Board MemberOxford Glycosciences 1996 - 2002Led strategy, business development, fundraising, and operations for this proteomics pioneer. We internally developed and achieved FDA and EU marketing approval for the rare orphan drug Zavesca to treat Gaucher's, later also approved for Niemann Pick disease. Took them public on the LSE and NASDAQ.
-
President And Coo, Member Of The BoardImmunex 1984 - 1996
Michael Kranda Education Details
-
Finance
Frequently Asked Questions about Michael Kranda
What company does Michael Kranda work for?
Michael Kranda works for Aclipse Therapeutics
What is Michael Kranda's role at the current company?
Michael Kranda's current role is Experienced Life Science Executive, VC, and Consultant | Driving growth, innovation, and value for Patients and Shareholders | 10+ Board Roles | 5+ Products to Market.
What schools did Michael Kranda attend?
Michael Kranda attended University Of Washington.
Who are Michael Kranda's colleagues?
Michael Kranda's colleagues are Kashaf Jabeen, Brian Moyer.
Not the Michael Kranda you were looking for?
-
Michael Kranda
Portland, Or -
5vulcan.com, alleninstitute.org, gmail.com, anesiva.com, anesiva.com -
Michael Kranda
Bellevue, Wa -
Michael Kranda
Medina, Wa
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial